17-Hydroxyprogesterone Caproate - Makena

Makena

A 2011 decision by the USFDA was going to result in driving "up the cost of an available medication from about $300 to $30,000 — about a 100-fold increase — with minimal added clinical benefit". However, the USFDA said it would not go after compounding pharmacies that filled prescriptions, and KV Pharmaceutical announced a lower price.